267 related articles for article (PubMed ID: 32399765)
21. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171
[TBL] [Abstract][Full Text] [Related]
22. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
Arachchillage DR; Laffan M
Semin Thromb Hemost; 2019 Sep; 45(6):604-611. PubMed ID: 31382304
[TBL] [Abstract][Full Text] [Related]
23. Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms.
Falanga A; Marchetti M; Schieppati F
Hamostaseologie; 2021 Feb; 41(1):48-57. PubMed ID: 33588455
[TBL] [Abstract][Full Text] [Related]
24. Are MPNs vascular diseases?
Finazzi G; De Stefano V; Barbui T
Curr Hematol Malig Rep; 2013 Dec; 8(4):307-16. PubMed ID: 24037420
[TBL] [Abstract][Full Text] [Related]
25. How to manage thrombosis in myeloproliferative neoplasms.
Barbui T
Curr Opin Oncol; 2011 Nov; 23(6):654-8. PubMed ID: 21986846
[TBL] [Abstract][Full Text] [Related]
26. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
27. Some aspects of platelet glucose metabolism in thrombocytosis due to myeloproliferative disorders.
Leoncini G; Maresca M; Balestrero F; Armani U; Piana A
Thromb Res; 1984 May; 34(3):233-9. PubMed ID: 6729778
[TBL] [Abstract][Full Text] [Related]
28. Bleeding and thrombosis in the myeloproliferative disorders.
Schafer AI
Blood; 1984 Jul; 64(1):1-12. PubMed ID: 6375757
[TBL] [Abstract][Full Text] [Related]
29. [Thrombosis in myeloproliferative neoplasms].
Asakura H
Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
[TBL] [Abstract][Full Text] [Related]
30. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
31. Platelet and plasma beta thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis.
Boughton BJ; Allington MJ; King A
Br J Haematol; 1978 Sep; 40(1):125-32. PubMed ID: 81681
[TBL] [Abstract][Full Text] [Related]
32. [Aggregative behavior and calcium content of platelets in thrombocythemia and thrombocytosis].
Hochhaus A; Mindner K; Ostermann G; Höche D
Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(6):765-70. PubMed ID: 1713878
[TBL] [Abstract][Full Text] [Related]
33. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.
Tefferi A; Elliott M
Semin Thromb Hemost; 2007 Jun; 33(4):313-20. PubMed ID: 17525888
[TBL] [Abstract][Full Text] [Related]
34. The Pitfalls of Global Hemostasis Assays in Myeloproliferative Neoplasms and Future Challenges.
Tiu A; Chiasakul T; Kessler CM
Semin Thromb Hemost; 2024 Mar; 50(2):213-223. PubMed ID: 37068511
[TBL] [Abstract][Full Text] [Related]
35. Disorders of hemostasis and thrombosis in the aged.
Hussain S
Med Clin North Am; 1976; 60(6):1273-87. PubMed ID: 790050
[No Abstract] [Full Text] [Related]
36. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.
Marin Oyarzún CP; Heller PG
Front Immunol; 2019; 10():1373. PubMed ID: 31258539
[TBL] [Abstract][Full Text] [Related]
37. [Essential thrombocytosis].
Van Camp G
Acta Clin Belg; 1989; 44(1):31-6. PubMed ID: 2763782
[TBL] [Abstract][Full Text] [Related]
38. Classification of thrombocytosis based on platelet function tests: correlation with hemorrhagic and thrombotic complications.
Zucker S; Mielke CH
J Lab Clin Med; 1972 Sep; 80(3):385-94. PubMed ID: 5055386
[No Abstract] [Full Text] [Related]
39. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
40. Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease.
Wehmeier A; Scharf RE; Fricke S; Schneider W
Haemostasis; 1989; 19(5):251-9. PubMed ID: 2777137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
